Neuropsychologic Assessments of Dupilumab-Treated Adolescents With Moderate-to-Severe Atopic Dermatitis
Latest Information Update: 12 Sep 2023
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms NEURADAD
- Sponsors Regeneron Pharmaceuticals
Most Recent Events
- 05 Sep 2023 Status changed from active, no longer recruiting to completed.
- 31 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 01 Mar 2022 Status changed from not yet recruiting to recruiting.